ABCL vs ALC
AbCellera Biologics Inc. vs Alcon Inc — AI-powered side-by-side comparison
ABCL
AbCellera Biologics Inc.
66
Buy
VS
| Metric | ABCL | ALC |
|---|
| AI Score |
66
|
68
|
| Price |
$9.75
|
$75.39
|
| P/E Ratio |
-18.07×
|
45.39×
|
| ROE |
-15.1%
|
4.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.0%
|
54.9%
|
| Debt / Equity |
0.15×
|
0.24×
|
| Dividend Yield |
0.0%
|
0.5%
|
| RSI (14) |
90.0
|
73.4
|
| Beta |
1.191
|
0.703
|
| Expected Upside |
—
|
+11.3%
|
AI Committee View
Current Innellis committee reasoning for ABCL versus ALC.
ALC leads by 2 points.
ALC scores 68/100 (Buy) versus ABCL at 66/100 (Buy).
ABCL Committee View
67% agreement
6 analysts
The primary driver is revenue growing 101.3% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 77.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Revenue growing 101.3% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- ROE of only -17.5% -- cheap may mean cheap for a reason — Value
- RSI at 90 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical